Rhythm Pharmaceuticals, Inc.
setmelanotide
acquired hypothalamic obesity
Resolved
113days ago
Phase 2 readout · Mar 16, 2026
What's at stake
Phase 2 trial results for setmelanotide in acquired hypothalamic obesity are due Mar 16, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Announce six-month results from the ongoing exploratory Phase 2 trial of setmelanotide in Prader-Willi Syndrome (PWS) in the second quarter of 2026;”